Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 60.1% in October

Rein Therapeutics Inc. (NASDAQ:RNTX) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 26,100 shares, a growth of 60.1% from the September 30th total of 16,300 shares. Based on an average daily volume of 139,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 139,100 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of brokerages recently commented on RNTX. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Brookline Capital Management upgraded Rein Therapeutics to a “buy” rating in a research report on Monday. HC Wainwright began coverage on Rein Therapeutics in a research report on Monday, September 22nd. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Loop Capital set a $6.00 price target on Rein Therapeutics in a research report on Monday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Insider Activity at Rein Therapeutics

In related news, major shareholder Voss Capital, Lp purchased 178,392 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were bought at an average price of $1.39 per share, for a total transaction of $247,964.88. Following the completion of the transaction, the insider owned 500,000 shares of the company’s stock, valued at approximately $695,000. This trade represents a 55.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders acquired a total of 306,050 shares of company stock valued at $423,460 in the last quarter. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Exencial Wealth Advisors LLC bought a new position in Rein Therapeutics in the second quarter valued at about $43,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Rein Therapeutics during the second quarter valued at about $716,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Rein Therapeutics during the second quarter valued at about $64,000. Blair William & Co. IL acquired a new stake in shares of Rein Therapeutics during the second quarter valued at about $33,000. Finally, Meridian Wealth Advisors LLC acquired a new stake in shares of Rein Therapeutics during the second quarter valued at about $40,000. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Stock Up 11.8%

Rein Therapeutics stock opened at $1.75 on Tuesday. Rein Therapeutics has a 12-month low of $1.04 and a 12-month high of $4.15. The business’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.49. The stock has a market cap of $40.78 million, a PE ratio of -0.65 and a beta of 1.14.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Thursday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). As a group, analysts expect that Rein Therapeutics will post -1.56 earnings per share for the current year.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.